Preparation and Characterization of Sodium Alginate Nanoparticles Containing ICD-85 (Venom Derived Peptides)

[1] M. Cegnar and J. Kerc, “Self-assembled Polyelectrolyte Nanocomplexes of Alginate, Chitosan and Ovalbumin”, Acta
Chim Slov, vol. 57, pp. 431–441, 2010.
[2] M. Leonard, M.R.D. Boisseson, P. Hubert, F. Dalenccon and E. Dellacherie, “Hydrophobically modified alginate hydrogels
as protein carriers with specific controlled release properties”, J Control Release, vol. 98, no. 3, pp. 395–405, 2004.
Saeed Moradhaseli, Abbas Zare Mirakabadi, Ali Sarzaeem, Nasser Mohammadpour dounighi, Saman Soheily, and Mehrasa
Rahimi Borumand
ISSN : 2028-9324 Vol. 4 No. 3, Nov. 2013 541
[3] A. Yurdasiper and F. Sevgi, “An overview of modified release chitosan, alginate and eudragit RS Microparticles”, J Chem
Pharm Res, vol. 2, no. 3, pp. 704–721, 2010.
[4] H.H. Tonnesen and J. Karlsen, “Alginate in drug delivery systems”, Drug Dev Ind Pharm, vol. 28, no. 6, pp. 621–630,
2002.
[5] M.G. Ferreiro, L. Tillman, G. Hardee and R. Bodmeier, “Characterization of alginate/poly-L-lysine particles as antisense
oligonucleotide carriers”, Int J Pharm, vol. 239, no. 1-2, pp. 47–59, 2002.
[6] G.W. Vandenberg, C. Drolet, S.L. Scott and J. de la Noue, “Factors affecting protein release from alginate-chitosan
coacervate microcapsules during production and gastric/intestinal simulation”, J Control Release, vol. 77, no. 3, pp. 297–
307, 2001.
[7] S. Cafaggi, E. Russo, R. Stefani, R. Leardi, G. Caviglioli, B. Parodi, G. Bignardi, D. De Totero, C. Aiello and M. Viale,
“Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin–alginate
complex”, J Control Release, vol. 121, no. 1-2, pp. 110–123, 2007.
[8] N.E. Simpson, S.C. Grant, L. Gustavsson, V.M. Peltonen, S.J. Blackband and I. Constantinidis, “Biochemical consequences
of alginate encapsulation: A NMR study of insulin-secreting cells”, Biomaterials, vol. 27, no. 12, pp. 2577–2586, 2006.
[9] N.E. Simpson, C.L. Stabler, C.P. Simpson, A. Sambanis and I. Constantinidis, “The role of the CaCl2-guluronic acid
interaction on alginate encapsulated βTC3 cells”, Biomaterials, vol. 25, no. 13, pp. 2603–2610, 2004.
[10] W.R. Gombotz and S.F. Wee, “Protein release from alginate matrices”, Adv Drug Deliver Rev, vol. 31, no. 3, pp. 267–285,
1998.
[11] D. Quong, R.J. Neufeld, G. Skjak-Braek and D. Poncelet, “External versus internal source of calcium during the gelation of
alginate beads for DNA encapsulation”, Biotechnol Bioeng, vol. 57, no. 4, pp. 438–446, 1998.
[12] L. Xing, C. Dawei, X. Liping and Z. Rongqing, “Oral colon-specific drug delivery for bee venom peptide: development of a
coated calcium alginate gel beads-entrapped liposome”, J Control Release, vol. 93, no. 3, pp. 293–300, 2003.
[13] A. Rezaei Mokarram, S.A. Mortazavi, N. Mohammadpour Dounighi, H. Zolfagharian and M.J. Alonso, “Preparation and
in-vitro evaluation of sodium alginate microspheres containing diphtheria toxoid as new vaccine delivery”, Arch Razi
Inst, vol. 63, no. 2, pp. 19–28, 2008.
[14] N.K.K. Raj and C.P. Sharma, “Oral insulin-a perspective”, J Biomater Appl, vol. 17, no. 3, pp.183–196, 2003.
[15] C. Vauthier and K. Bouchemal, “Methods for the preparation and manufacture of polymeric nanoparticles”, Pharm Res,
vol. 26, no. 5, pp. 1025–1058, 2009.
[16] M. Rajaonarivony, C. Vauthier, G. Couarraze, F. Puisieux and P. Couvreur, “Development of a new drug carrier made
from alginate”, J Pharm Sci, vol. 82, no. 9, pp. 912–917, 1993.
[17] W. Tiyaboonchai, “Chitosan Nanoparticles: A Promising System for Drug Delivery”, Naresuan University Journal, vol. 11,
no. 3, pp. 51–66, 2003.
[18] S. De and D. Robinson, “Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate
nanospheres”, J Control Release, vol. 89, no. 1, pp. 101–112, 2003.
[19] Y. Yang, Q. He, L. Duan, Y. Cui and J. Li, “Assembled alginate/chitosan nanotubes for biological application”,
Biomaterials, vol. 28, no. 20, pp. 3083–3090, 2007.
[20] E. Gullotti and Y. Yeo, “Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery”, Mol
Pharm, vol. 6, no. 4, pp. 1041–1051, 2009.
[21] X. Yang, Q. Zhang, Y. Wang, H. Chen, H. Zhang, F. Gao and L. Liu, “Self-aggregated nanoparticles from methoxy poly
(ethylene glycol)-modified chitosan: synthesis; characterization; aggregation and methotrexate release in vitro”, Colloids
Surf B: Biointerfaces, vol. 61, no. 2, pp. 125–131, 2008.
[22] L. Mu and S.S. Feng, “A novel controlled release formulation for the anticancer drug Paclitaxel (Taxol(R)): PLGA
nanoparticles containing vitamin E TPGS”, J Control Release, vol. 86, no. 1, pp. 33–48, 2003.
[23] F. Kratz, “Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles”, J Control Release, vol. 132,
no. 3, pp. 171–183, 2008.
[24] A. Martínez, I. Iglesias, R. Lozano, J.M. Teijón and M.D. Blanco, “Synthesis and characterization of thiolated alginate
albumin nanoparticles stabilized by disulfide bonds, Evaluation as drug delivery systems”, Carbohyd Polym, vol. 83, no.
3, pp. 1311–1321, 2011.
[25] J. Zhang, X.G. Chen, Y.Y. Li and C.S. Liu, “Self-assembled nanoparticles based on hydrophobically modified chitosan as
carriers for doxorubicin”, Nanomedicine, vol. 3, no. 4, pp. 258–265, 2007.
[26] F-Q. Hu, G-F. Ren, H. Yuan, Y-Z. Du and S. Zeng, “Shell cross-linked stearic acid grafted chitosan oligosaccharide selfaggregated
micelles for controlled release of paclitaxel”, Colloids Surf B: Biointerfaces, vol. 50, no. 2, pp. 97–103, 2006.
[27] J.K. Sarmah, R. Mahanta, S.K. Bhattacharjee and A. Biswas, “Controlled release of tamoxifen citrate encapsulated in
cross-linked guar gum nanoparticles”, Int J Biol Macromol, vol. 49, no. 3, pp. 390–396, 2011.
Preparation and Characterization of Sodium Alginate Nanoparticles Containing ICD-85 (Venom Derived Peptides)
ISSN : 2028-9324 Vol. 4 No. 3, Nov. 2013 542
[28] A. Zare Mirakabadi, S. Mahdavi, M.K. Koohi and M. Taghavian, “Cytotoxic effect of ICD-85 (venom-derived peptides) on
MDA-MB-231 cell line”, J Venom Anim Toxins incl Trop Dis, vol. 14, no. 4, pp. 619–627, 2008.
[29] A. Zare Mirakabadi, Z. Shahramyar, H. Morovvati, M. Lotfi and A. Nouri, “Induction of Apoptosis in Human Leukemia Cell
line (HL-60) by animal's venom derived peptides (ICD-85)”, Iran J Pharm Res, vol. 11, no. 3, pp. 931-938, 2012.
[30] M.K. Koohi, A. Zare Mirakabadi, M. Moharrami and M.H. Hablolvarid, “Anticancer effect of ICD-85 (venom derived
peptides) on MDA-MB231 cell line (in vitro) and experimental mice with breast cancer (in vivo)”, Int J Vet Res, vol. 3, no.
1, pp. 49–54, 2009.
[31] M.M. Bradford, “A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding”, Anal Biochem, vol. 72, no. 1-2, pp. 248–254, 1976.
[32] N. Mohammadpour Dounighi, R. Eskandari, M.R. Avadi, H. Zolfagharian, A. Mir Mohammad Sadeghi and M. Rezayat,
“Preparation and in vitro characterization of chitosan nanoparticles containing Mesobuthus eupeus scorpion venom as
an antigen delivery system”, J Venom Anim Toxins incl Trop Dis, vol. 18, no. 1, pp. 44–52, 2012.
[33] R.I. Freshney, Subculture and cell Lines. In: Culture of animal cells: a manual of basic technique and specialized
applications, 6th ed, New York, Wiley-Liss, pp. 187– 206, 2010.
[34] T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity
assay”, J Immunol Methods, vol. 65, no. 1-2, pp. 55–63, 1983.
[35] R. Duncan, ‘Polymer conjugates as anticancer nanomedicines”, Nat Rev Cancer, vol. 6, no. 9, pp. 688–701, 2006.
[36] A. Wang and S. Li, “Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect”,
BMC Biotechnol, vol. 8, no. 1, pp. 46, 2008.
[37] S. Yadav, L.E. Van Vlerken, S.R. Little, and M.M. Amiji, “Evaluations of combination MDR-1 gene silencing and paclitaxel
administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells”,
Cancer Chemother Pharmacol, vol. 63, no. 4, pp. 711–722, 2009.
[38] Z. Zhang, S.H Lee, C.W Gan and S-S. Feng, “In vitro and in vivo investigation on PLA–TPGS nanoparticles for controlled
and sustained small molecule chemotherapy”, Pharm Res, vol. 25, no. 8, pp. 1925–1935, 2008.
[39] M. Mombeinipour, A. Zare Mirakabadi, K. Mansuri and M. Lotfi, “In vivo and In vitro Anti-angiogenesis Effect of Venomderived
Peptides (ICD-85)”, Arch Iran Med, vol. 16, no. 2, pp. 109–113, 2013.
[40] S.K. Motwani, S. Chopra, S. Talegaonkar, K. Kohli, F.J. Ahmad and R.K. Khar, “Chitosan–sodium alginate nanoparticles as
submicroscopic reservoirs for ocular delivery: Formulation, optimization and in vitro characterization”, Eur J Pharm
Biopharm, vol. 68, no.3, pp. 513–525, 2008.
[41] S. Prabha, W-Z Zhou, J. Panyam and V. Labhasetwar, “Size-dependency of nanoparticle-mediated gene transfection:
studies with fractionated nanoparticles”, Int J Pharm, vol. 244, no. 1-2, pp. 105–115, 2002.
[42] S.G. Yang, J.E. Chang, B. Shin, S. Park, K. Na and C.K. Shim, “99mTchematoporphyrin linked albumin nanoparticles for
lung cancer targeted photodynamic therapy and imaging”, J Mater Chem, vol. 20, pp. 9042–9046, 2010.
[43] VJ. Mohanraj and Y. Chen, “Nanoparticles – A Review”, Trop J Pharm Res, vol. 5, no. 1, pp. 561–573, 2006.
[44] F. Yan, C. Zhang, Y. Zheng, L. Mei, L. Tang, C. Song and et al, “The effect of poloxamer 188 on nanoparticle morphology,
size, cancer cell uptake, and cytotoxicity”, Nanomedicine, vol. 6, no. 1, pp. 170–178, 2010.
[45] C. Hian Goh, P. Wan Sia Heng and L.W. Chan, “Alginates as a useful natural polymer for microencapsulation and
therapeutic applications”, Carbohyd Polym, vol. 88, no. 1, pp. 1–12, 2012.
[46] I. Brigger, C. Dubernet and P. Couvreur, “Nanoparticles in cancer therapy and diagnosis”, Adv Drug Deliv Rev, vol. 54, no.
5, pp. 631–651, 2002.
[47] G. Mattheolabakis, E. Taoufik, S. Haralambous, ML. Roberts and K. Avgoustakis, “In vivo investigation of tolerance and
antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles”, Eur J Pharm Biopharm, vol. 71, no. 2, pp. 190–195,
2009.
[48] L. Zhang, M. Yang, Q. Wang, Y. Li, R. Guo, X. Jiang and et al, “10- Hydroxycamptothecin loaded nanoparticles:
preparation and antitumor activity in mice”, J Control Release, vol. 119, no. 2, pp. 153–162, 2007.
[49] M. Hong, S. Zhu, Y. Jiang, G. Tang, C. Sun, C. Fang and et al, “Novel anti-tumor strategy: PEG-hydroxycamptothecin
conjugate loaded transferrin-PEG-nanoparticles”, J Control Release, vol. 141,no. 1, pp. 22–29, 2010.
[50] J. Ravindran, H.B. Nair, B. Sung, S. Prasad, R.R. Tekmal and B.B. Aggarwal, “Thymoquinone poly (lactide-co-glycolide)
nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential”, Biochem
Pharm, vol. 79, no. 11, pp. 1640–1647, 2010.
[51] X. Li, R. Li, X. Qian, Y. Ding, Y. Tu, R. Guo and et al, “Superior antitumor efficiency of cisplatin-loaded nanoparticles by
intratumoral delivery with decreased tumor metabolism rate”, Eur J Pharm Biopharm, vol. 70, no. 3, pp. 726–734, 2008.